1
|
Patel P, Pathak A, Jain K. Novel ligand decorated theranostic zein nanoparticles coloaded with paclitaxel and carbon quantum dots: formulation and optimization. Nanomedicine (Lond) 2024; 19:367-382. [PMID: 38305304 DOI: 10.2217/nnm-2023-0197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2024] Open
Abstract
Aim: The present research focused on development and optimization of ligand decorated theranostic nanocarrier encapsulating paclitaxel and carbon quantum dots (CQDs). Methods: CQDs were prepared by microwave-assisted pyrolysis and were characterized for particle size and fluorescence behavior. Ligand decorated zein nanoparticles, coloaded with paclitaxel and CQDs, were formulated using a one-step nanoprecipitation method and optimized for various process parameters. Results: Particle size for coated and uncoated nanoparticles was 90.16 ± 1.65 and 179.26 ± 3.61 nm, respectively, and entrapment efficiency was >80%. The circular dichroism spectroscopy showed zein retained its secondary structure and release study showed biphasic release behavior. Conclusion: The prepared theranostic nanocarrier showed optimal fluorescence and desired release behavior without altering the secondary structure of zein.
Collapse
Affiliation(s)
- Parth Patel
- Drug Delivery & Nanomedicine Research Laboratory, Department of Pharmaceutics, National Institute of Pharmaceutical Education & Research (NIPER) - Raebareli, Lucknow, 226002, India
| | - Anchal Pathak
- Drug Delivery & Nanomedicine Research Laboratory, Department of Pharmaceutics, National Institute of Pharmaceutical Education & Research (NIPER) - Raebareli, Lucknow, 226002, India
| | - Keerti Jain
- Drug Delivery & Nanomedicine Research Laboratory, Department of Pharmaceutics, National Institute of Pharmaceutical Education & Research (NIPER) - Raebareli, Lucknow, 226002, India
| |
Collapse
|
2
|
Designing Formulation Strategies for Enhanced Stability of Therapeutic Peptides in Aqueous Solutions: A Review. Pharmaceutics 2023; 15:pharmaceutics15030935. [PMID: 36986796 PMCID: PMC10056213 DOI: 10.3390/pharmaceutics15030935] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Revised: 03/04/2023] [Accepted: 03/09/2023] [Indexed: 03/15/2023] Open
Abstract
Over the past few decades, there has been a tremendous increase in the utilization of therapeutic peptides. Therapeutic peptides are usually administered via the parenteral route, requiring an aqueous formulation. Unfortunately, peptides are often unstable in aqueous solutions, affecting stability and bioactivity. Although a stable and dry formulation for reconstitution might be designed, from a pharmaco-economic and practical convenience point of view, a peptide formulation in an aqueous liquid form is preferred. Designing formulation strategies that optimize peptide stability may improve bioavailability and increase therapeutic efficacy. This literature review provides an overview of various degradation pathways and formulation strategies to stabilize therapeutic peptides in aqueous solutions. First, we introduce the major peptide stability issues in liquid formulations and the degradation mechanisms. Then, we present a variety of known strategies to inhibit or slow down peptide degradation. Overall, the most practical approaches to peptide stabilization are pH optimization and selecting the appropriate type of buffer. Other practical strategies to reduce peptide degradation rates in solution are the application of co-solvency, air exclusion, viscosity enhancement, PEGylation, and using polyol excipients.
Collapse
|
3
|
Development of Self-Administered Formulation to Improve the Bioavailability of Leuprorelin Acetate. Pharmaceutics 2022; 14:pharmaceutics14040785. [PMID: 35456619 PMCID: PMC9031317 DOI: 10.3390/pharmaceutics14040785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 03/28/2022] [Accepted: 04/01/2022] [Indexed: 02/05/2023] Open
Abstract
In recent years, the development of self-injectable formulations has attracted much attention, and the development of formulations to control pharmacokinetics, as well as drug release and migration in the skin, has become an active research area. In the present study, the development of a lipid-based depot formulation containing leuprorelin acetate (LA) as an easily metabolizable drug in the skin was prepared with a novel non-lamellar liquid-crystal-forming lipid of mono-O-(5,9,13-trimethyl-4-tetradecenyl) glycerol ester (MGE). Small-angle X-ray scattering, cryo-transmission electron microscopy, and nuclear magnetic resonance observations showed that the MGE-containing formulations had a face-centered cubic packed micellar structure. In addition, the bioavailability (BA) of LA after subcutaneous injection was significantly improved with the MGE-containing formulation compared with the administration of LA solution. Notably, higher Cmax and faster Tmax were obtained with the MGE-containing formulation, and the BA increased with increasing MGE content in the formulation, suggesting that LA migration into the systemic circulation and its stability might be enhanced by MGE. These results may support the development of self-administered formulations of peptide drugs as well as nucleic acids, which are easily metabolized in the skin.
Collapse
|
4
|
Skiba M, Fatmi S, Elkasri N, Karrout Y, Lahiani-Skiba M. Development, validation and method stability study of a LC-MS method to quantify leuprolide (Hormone analog) in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2020; 1160:122345. [PMID: 32920482 DOI: 10.1016/j.jchromb.2020.122345] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2020] [Revised: 08/08/2020] [Accepted: 08/20/2020] [Indexed: 11/16/2022]
Abstract
A rapid, highly sensitive and simple high-performance liquid chromatographic-tandem mass spectrometric (LC-MS) assay is developed and validated for the quantification of leuprolide: a Gonadotropin Releasing Hormone analog (GnRH) in human plasma. Moreover, various parameters of the method stability are determined. After the addition of stable isotope (internal standard), the leuprolide was extracted from human plasma by a C18 solid phase micro extraction (MEPS) cartridge and directly injected into LC-MS/MS system. Chromatographic separation was achieved using a Waters Atlantis HILIC, C18, 150 × 2.1 mm, 5 μ column. Mobile phase was a mixture of acetate buffer (pH 3) and acetonitrile (25/75). Drug detection was performed by MS using electrospray ionization in positive mode. Multiple reaction monitoring (MRM) with a tandem mass spectrometer was used to detect the analytes. Precursor to product ion transitions of: m/z 605.5 → m/z 110.2 and m/z 609.1 → m/z 249.1 were used to quantify leuprolide and leuprolide-13C6-15N, respectively. Sample analysis time was 3 min for each injection. The assay exhibited a linear dynamic range of 0.0500-40 ng/ml for each analyte with a lower limit of quantification (LLOQ) of: 0.0500 ng/ml. Furthermore, a complete analytic validation was carried out, including tests on: The specificity, precision, accuracy, matrix effect and stability under different storage conditions. Importantly, the obtained results established: an acceptable precision and accuracy for concentration over standard curve range. Nevertheless, it is to emphasize the simplicity, rapidity and also the high precision and accuracy of this novel LC-MS method, offering useful information about solution stability. Finally, this work is a good alternative to quantify Leuprolide concentration in human blood, especially on human clinic trials step.
Collapse
Affiliation(s)
- M Skiba
- Normandy UNIV, UNIROUEN, Galenic Pharmaceutical Team, UFR of Health, 22 boulevard Gambetta, 76000 Rouen, France; Normandy UNIV, UNIROUEN, DC2N INSERM U1239, Mont Saint-Aignan, France
| | - S Fatmi
- Normandy UNIV, UNIROUEN, Galenic Pharmaceutical Team, UFR of Health, 22 boulevard Gambetta, 76000 Rouen, France; Technology Pharmaceutical Laboratory, Department of Processes Engineering, Faculty of Technology, Université de Bejaia, 06000 Bejaia, Algeria.
| | - N Elkasri
- Normandy UNIV, UNIROUEN, Galenic Pharmaceutical Team, UFR of Health, 22 boulevard Gambetta, 76000 Rouen, France
| | - Y Karrout
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - M Lahiani-Skiba
- Normandy UNIV, UNIROUEN, Galenic Pharmaceutical Team, UFR of Health, 22 boulevard Gambetta, 76000 Rouen, France; Normandy UNIV, UNIROUEN, DC2N INSERM U1239, Mont Saint-Aignan, France
| |
Collapse
|
5
|
Khodaverdi E, Eisvand F, Nezami MS, Shiadeh SNR, Kamali H, Hadizadeh F. Injectable In-Situ Forming Depot of Doxycycline Hyclate/α-Cyclodextrin Complex Using PLGA for Periodontitis Treatment: Preparation, Characterization, and In-Vitro Evaluation. Curr Drug Deliv 2020; 18:729-740. [PMID: 33155908 DOI: 10.2174/1567201817999201103195104] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2020] [Revised: 07/29/2020] [Accepted: 09/25/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Doxycycline (DOX) is used in treating a bacterial infection, especially for periodontitis treatment. OBJECTIVE To reduce irritation of DOX for subgingival administration and increase the chemical stability and against enzymatic, the complex of α-cyclodextrin with DOX was prepared and loaded into injectable in situ forming implant based on PLGA. METHODS FTIR, molecular docking studies, X-ray diffraction, and differential scanning calorimetry was performed to characterize the DOX/α-cyclodextrin complex. Finally, the in-vitro drug release and modeling, morphological properties, and cellular cytotoxic effects were also evaluated. RESULTS The stability of DOX was improved with complex than pure DOX. The main advantage of the complex is the almost complete release (96.31 ± 2.56 %) of the drug within 14 days of the implant, whereas in the formulation containing the pure DOX and the physical mixture the DOX with α-cyclodextrin release is reached to 70.18 ± 3.61 % and 77.03 ± 3.56 %, respectively. This trend is due to elevate of DOX stability in the DOX/ α-cyclodextrin complex form within PLGA implant that confirmed by the results of stability. CONCLUSION Our results were indicative that the formulation containing DOX/α-cyclodextrin complex was biocompatible and sustained-release with minimum initial burst release.
Collapse
Affiliation(s)
- Elham Khodaverdi
- Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Farhad Eisvand
- Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Mohammad Sina Nezami
- Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Seyedeh Nesa Rezaeian Shiadeh
- Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Hossein Kamali
- Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Farzin Hadizadeh
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
| |
Collapse
|
6
|
Andhariya JV, Jog R, Shen J, Choi S, Wang Y, Zou Y, Burgess DJ. Development of Level A in vitro-in vivo correlations for peptide loaded PLGA microspheres. J Control Release 2019; 308:1-13. [DOI: 10.1016/j.jconrel.2019.07.013] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2019] [Revised: 06/29/2019] [Accepted: 07/09/2019] [Indexed: 01/04/2023]
|
7
|
Hutchinson JA, Burholt S, Hamley IW. Peptide hormones and lipopeptides: from self-assembly to therapeutic applications. J Pept Sci 2017; 23:82-94. [PMID: 28127868 PMCID: PMC5324658 DOI: 10.1002/psc.2954] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2016] [Revised: 11/24/2016] [Accepted: 11/27/2016] [Indexed: 12/18/2022]
Abstract
This review describes the properties and activities of lipopeptides and peptide hormones and how the lipidation of peptide hormones could potentially produce therapeutic agents combating some of the most prevalent diseases and conditions. The self‐assembly of these types of molecules is outlined, and how this can impact on bioactivity. Peptide hormones specific to the uptake of food and produced in the gastrointestinal tract are discussed in detail. The advantages of lipidated peptide hormones over natural peptide hormones are summarised, in terms of stability and renal clearance, with potential application as therapeutic agents. © 2017 The Authors Journal of Peptide Science published by European Peptide Society and John Wiley & Sons Ltd.
Collapse
Affiliation(s)
- J A Hutchinson
- Department of Chemistry, University of Reading, Whiteknights, Reading, RG6 6AD, UK
| | - S Burholt
- Department of Chemistry, University of Reading, Whiteknights, Reading, RG6 6AD, UK
| | - I W Hamley
- Department of Chemistry, University of Reading, Whiteknights, Reading, RG6 6AD, UK
| |
Collapse
|
8
|
Rahimi M, Mobedi H, Behnamghader A. In situ-forming PLGA implants loaded with leuprolide acetate/β-cyclodextrin complexes: mathematical modelling and degradation. J Microencapsul 2016; 33:355-64. [DOI: 10.1080/02652048.2016.1194905] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
9
|
Inagaki H, Ito R, Setoguchi Y, Oritani Y, Ito T. Administration of Piceatannol Complexed with α-Cyclodextrin Improves Its Absorption in Rats. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2016; 64:3557-3563. [PMID: 27078058 DOI: 10.1021/acs.jafc.6b00398] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Piceatannol is polyphenolic antioxidant found in passion fruit (Passiflora edulis) seeds. The aim of this study was to improve the absorption of piceatannol using α-cyclodextrin (αCD). The solubility of piceatannol in neutral and acidic solutions increased in an αCD concentration-dependent manner. The maximum plasma concentration of intact piceatannol and the time-to-maximum plasma concentration of O-methylated piceatannol metabolites increased in rats administered αCD-piceatannol inclusion complexes (PICs). Administering the αCD inclusion complexes significantly increased the area under the concentration-time curve of total stilbene derivatives (0-3 h) in terms of the total amount of intact piceatannol, O-methylated piceatannol, conjugated piceatannol, and isorhapontigenin. Gastrointestinal ligation experiments demonstrated that substantially higher levels of piceatannol metabolites were present in the lower intestine (the ileum) at 1 h postintragastric αCD-PICs administration as compared to those observed following piceatannol administration only. These results suggested that αCD enhanced piceatannol movement and absorption in the small intestine.
Collapse
Affiliation(s)
- Hiroyuki Inagaki
- Research Institute, Morinaga & Company, Ltd. , 2-1-1 Shimosueyoshi, Tsurumi-ku, Yokohama, Kanagawa 230-8504, Japan
| | - Ryouichi Ito
- Research Institute, Morinaga & Company, Ltd. , 2-1-1 Shimosueyoshi, Tsurumi-ku, Yokohama, Kanagawa 230-8504, Japan
| | - Yuko Setoguchi
- Research Institute, Morinaga & Company, Ltd. , 2-1-1 Shimosueyoshi, Tsurumi-ku, Yokohama, Kanagawa 230-8504, Japan
| | - Yukihiro Oritani
- Research Institute, Morinaga & Company, Ltd. , 2-1-1 Shimosueyoshi, Tsurumi-ku, Yokohama, Kanagawa 230-8504, Japan
| | - Tatsuhiko Ito
- Research Institute, Morinaga & Company, Ltd. , 2-1-1 Shimosueyoshi, Tsurumi-ku, Yokohama, Kanagawa 230-8504, Japan
| |
Collapse
|
10
|
Rahimi M, Mobedi H, Behnamghader A. In situforming poly(lactic acid-co-glycolic acid) implants containing leuprolide acetate/β-cyclodextrin complexes: preparation, characterization, andin vitrodrug release. INT J POLYM MATER PO 2015. [DOI: 10.1080/00914037.2015.1055633] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|